Get the Stockscreener App
70.82
0.45%
0.32
Henry Schein Inc stock is traded at $70.82, with a volume of 1.44M.
It is up +0.45% in the last 24 hours and down -6.24% over the past month.
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
See More
Previous Close:
$70.50
Open:
$70.67
24h Volume:
1.44M
Relative Volume:
1.02
Market Cap:
$8.07B
Revenue:
$13.18B
Net Income/Loss:
$419.00M
P/E Ratio:
21.65
EPS:
3.2704
Net Cash Flow:
$521.00M
1W Performance:
-4.21%
1M Performance:
-6.24%
6M Performance:
-1.50%
1Y Performance:
+2.80%
1-Day Range:
$69.34
$71.35
1-Week Range:
$69.34
$76.03
52-Week Range:
$61.95
$89.29
Henry Schein Inc Stock (HSIC) Company Profile
Name
Henry Schein Inc
Sector
Industry
Phone
(631) 843-5500
Address
135 DURYEA RD, MELVILLE, NY
Compare HSIC vs MCK, COR, CAH, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
70.82 | 8.07B | 13.18B | 419.00M | 521.00M | 3.2704 |
MCK
Mckesson Corp
|
736.09 | 88.33B | 397.96B | 4.55B | 9.64B | 34.77 |
COR
Cencora Inc
|
261.08 | 50.80B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
183.65 | 43.01B | 250.74B | 1.55B | 4.39B | 6.5398 |
AHG
Akso Health Group Adr
|
1.98 | 1.70B | 14.85M | -136.07M | 7.25M | -0.4726 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Initiated | BTIG Research | Neutral |
| Apr-15-26 | Initiated | Citigroup | Buy |
| Feb-23-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-26-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-25-25 | Downgrade | Stifel | Buy → Hold |
| Jul-14-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-14-25 | Initiated | Wells Fargo | Equal Weight |
| Jan-06-25 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Jul-22-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-10-23 | Upgrade | Stifel | Hold → Buy |
| Aug-08-22 | Upgrade | UBS | Sell → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| Jan-31-22 | Initiated | Morgan Stanley | Underweight |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Oct-01-21 | Resumed | Credit Suisse | Neutral |
| Feb-08-21 | Resumed | Piper Sandler | Overweight |
| Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
| Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Jan-17-19 | Initiated | UBS | Sell |
| Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
| Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-08-18 | Reiterated | Barrington Research | Outperform |
| Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
| Oct-19-18 | Resumed | Goldman | Neutral |
| Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
| Aug-07-18 | Reiterated | Stifel | Hold |
| Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
| Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc Stock (HSIC) Latest News
Henry Schein tops expectations, but shares dip slightly after results - MSN
Henry Schein Inc stock (US8064071025): Dental and medical distributor reports Q1 results and raises - AD HOC NEWS
Henry Schein, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - 富途牛牛
Henry Schein, Inc. Just Recorded A 8.1% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Earnings Beat: Henry Schein, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Henry Schein Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Number of shareholders of Henry Schein, Inc. – MIL:1HSIC - TradingView
Henry Schein’s THRIVELIVE 2026 Delivers on Innovation, Education, and Inspiration - Dentistry Today
Henry Schein Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Henry Schein Still Sees 2026 Adjusted Ebitda Up Mid-Single Digits >HSIC - Moomoo
Here's why Henry Schein (HSIC) is a strong value stock - MSN
Transcript: Henry Schein Q1 2026 Earnings Conference Call - Sahm
UBS Adjusts Price Target on Henry Schein to $85 From $87, Maintains Neutral Rating - marketscreener.com
Here's Why Henry Schein (HSIC) is a Strong Value Stock - Yahoo Finance
Henry Schein, Inc. (NASDAQ:HSIC) Q1 2026 Earnings Call Transcript - Insider Monkey
Henry Schein Inc. stock outperforms competitors on strong trading day - MarketWatch
Henry Schein Q1 Earnings Call Highlights - Yahoo Finance
Henry Schein (HSIC) Q1 2026 Earnings Call Transcript - Fortune
Piper Sandler Cuts Price Target on Henry Schein to $91 From $99 - marketscreener.com
Jefferies Adjusts Price Target on Henry Schein to $80 From $89, Maintains Hold Rating - marketscreener.com
Henry Schein (Nasdaq: HSIC) reports Q1 2026 net sales of $3,368M - Stock Titan
Tranche Update on Henry Schein, Inc.'s Equity Buyback Plan announced on December 13, 2018. - marketscreener.com
Henry Schein Q1 2026 Earnings Call Transcript - MarketBeat
Henry Schein, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Henry Schein (HSIC) Q1 2026 Earnings Transcript - AOL.com
Henry Schein Fiscal Q1 Non-GAAP Earnings, Net Sales Rise; Reaffirms 2026 Outlook - Moomoo
Earnings call transcript: Henry Schein Q1 2026 beats expectations, stock dips - Investing.com
Compared to Estimates, Henry Schein (HSIC) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
HSIC Q1 Earnings & Revenues Surpass Estimates, Gross Margin Rises - TradingView
Henry Schein, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HSIC) 2026-05-05 - Seeking Alpha
Q1 2026 Henry Schein Inc Earnings Call Transcript - GuruFocus
Henry Schein, Inc. Reports Earnings Results for the First Quarter Ended March 28, 2026 - marketscreener.com
Henry Schein : Q1 2026 Earnings Conference Call - marketscreener.com
Henry Schein reaffirms annual profit forecast, beats Q1 estimates on dental strength - marketscreener.com
Henry Schein Inc (NASDAQ:HSIC) Surges After Q1 Earnings Beat - ChartMill
Henry Schein : First Quarter 2026 Financial Presentation - marketscreener.com
Henry Schein beats estimates but stock edges down - Investing.com India
Henry Schein beats estimates but stock edges down By Investing.com - Investing.com Nigeria
Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Earnings Flash (HSIC) Henry Schein, Inc. Reports Q1 Revenue $3.37B, vs. FactSet Est of $3.34B - marketscreener.com
Earnings Flash (HSIC) Henry Schein, Inc. Posts Q1 Adjusted EPS $1.32 per Share, vs. FactSet Est of $1.22 - marketscreener.com
(HSIC) Henry Schein Expects Fiscal 2026 Non-GAAP EPS Range $5.23 to $5.37, vs. FactSet Est of $5.32 - marketscreener.com
Henry Schein (NASDAQ:HSIC) Beats Q1 CY2026 Sales Expectations - TradingView
Henry Schein (NASDAQ: HSIC) Q1 2026 sales up 6.3% as EPS jumps - Stock Titan
GUIDANCE: (HSIC) Henry Schein Expects Fiscal 2026 Non-GAAP EPS Range $5.23 to $5.37, Vs. FactSet Est of $5.32 - Moomoo
Henry Schein Q1 adjusted profit beats estimates - TradingView
Henry Schein: Q1 Earnings Snapshot - marketscreener.com
Henry Schein backs $200M income-improvement plan after Q1 - Stock Titan
Henry Schein Reports First Quarter 2026 Financial Results - marketscreener.com
Henry Schein, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2026 - marketscreener.com
Henry Schein (HSIC) Margins Hold Near 3% And Keep Profitability Debate Alive Heading Into Q1 - Sahm
Henry Schein Inc Stock (HSIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.41%
8.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):